"Traditional open-heart surgery is a very safe and effective way to replace diseased heart valves, but for many patients bypass surgery is not a viable option", stated Patrick M. McCarthy, MD, Northwestern Memorial's chief of cardiothoracic surgery and co-director of its Bluhm Institute and a Heller-Sacks professor of surgery at Northwestern University's Feinberg School of Medicine. "By utilizing the percutaneous technique - meaning surgery is not required - we are able to greatly reduce risk for these patients. We see percutaneous valve repair as not only having a great impact upon how high-risk patients are treated, but in how heart valve disease is treated in the United States and around the world."
Dr. McCarthy is a co-principal investigator for the clinical trial that provided Irvin Lafferty's new heart valve, which is formally referred to as the Placement of AoRTic TraNscathetER Valve, or PARTNER. The Bluhm Institute is among the trial's pioneering sites. Dr. McCarthy said the procedure builds upon a routine catheter-based procedure, the balloon aortic valvuloplasty.
"Balloon aortic valvuloplasty has been traditionally offered as a palliative therapy for patients who were not candidates for aortic valve surgery", stated the hospital's Director of the Cardiac Catheterization Laboratory Charles J. Davidson, MD, who is also a co-principal investigator for the trial and a professor of medicine at Northwestern University's Feinberg School of Medicine. "This particular technique is a more durable treatment than balloon valvuloplasty and is potentially a breakthrough for treating high-risk patients."
Medical experts estimate every year nearly 200.000 people in the United States need new heart valves. Yet over half of them do not receive them primarily due to frailty, one of the most common reasons for exclusion from traditional open-heart surgery.
"Surgery becomes far too risky when patients are conditionally weak or frail", stated Chris Malaisrie, MD, a Northwestern Memorial cardiac surgeon and member of the site team evaluating this new procedure. "The goal is to replace diseased valve at minimal risk to these patients - many of whom have very limited therapeutic options. Aortic valve replacement is one of few therapies offering both symptomatic relief and improved long-term survival."
During insertion, the artificial valve remains collapsed until it reaches its destination. It is then expanded and released in place of diseased aortic heart valves. The prosthesis is made of stainless steel and biological leaflets that help direct the flow of blood in the heart. It is permanent and integrates an expandable stent that holds the valve in its intended position. Northwestern Memorial utilizes both the transfemoral - through the groin - and transapical - through the ribs - approaches. Implantation occurs in a hybrid operating room (OR) suite that incorporates elements of both a traditional OR and catheterization laboratory.
Dr. Patrick McCarthy, the Principal Investigator for this study, is a consultant for Edwards Lifesciences (for valve repair, not the study device used in the PARTNER trial), the manufacturer of the investigational valve. In addition, Dr. McCarthy receives royalties from 3 annuloplasty rings developed with Edwards (Edwards MC3 tricuspid system, Myxo ETlogix, and the Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring or CMA IMR ring.
Northwestern Memorial Hospital is one of the United States' premier academic medical centres and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine. Along with its Prentice Women's Hospital and Stone Institute of Psychiatry, the hospital comprises 873 beds, 1554 affiliated physicians and 6747 employees. Northwestern Memorial is recognized for providing exemplary patient care and state-of-the art advancements in the areas of cardiovascular care; women's health; oncology; neurology and neurosurgery; solid organ and soft tissue transplants and orthopaedics. More news about the hospital is available in this VMW issue's article Gallbladder removal through vagina offers minimally invasive alternative.
For more information about the Bluhm Cardiovascular Institute and the treatment of aortic valve stenosis you can visit the Northwestern Memorial Hospital website.